DK1734959T3 - Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter - Google Patents

Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter

Info

Publication number
DK1734959T3
DK1734959T3 DK05732721.5T DK05732721T DK1734959T3 DK 1734959 T3 DK1734959 T3 DK 1734959T3 DK 05732721 T DK05732721 T DK 05732721T DK 1734959 T3 DK1734959 T3 DK 1734959T3
Authority
DK
Denmark
Prior art keywords
schizophrenia
compounds
treatment
glucoregulatory
abnormalities
Prior art date
Application number
DK05732721.5T
Other languages
English (en)
Inventor
Craig P Smith
David E Rampe
Beth Borowsky
Sathapana Kongsamut
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1734959T3 publication Critical patent/DK1734959T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05732721.5T 2004-04-01 2005-04-01 Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter DK1734959T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01
PCT/US2005/011107 WO2005097122A2 (en) 2004-04-01 2005-04-01 Method of treating schizophrenia and/or glucoregulatory abnormalities

Publications (1)

Publication Number Publication Date
DK1734959T3 true DK1734959T3 (da) 2010-03-08

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05732721.5T DK1734959T3 (da) 2004-04-01 2005-04-01 Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter

Country Status (26)

Country Link
US (1) US20070129403A1 (da)
EP (2) EP1734959B1 (da)
JP (1) JP2007531730A (da)
KR (1) KR20070010161A (da)
CN (1) CN1946399A (da)
AR (1) AR048197A1 (da)
AT (1) ATE446754T1 (da)
AU (1) AU2005231446A1 (da)
BR (1) BRPI0509512A (da)
CA (1) CA2561162A1 (da)
CL (1) CL2009001605A1 (da)
CY (1) CY1109734T1 (da)
DE (1) DE602005017373D1 (da)
DK (1) DK1734959T3 (da)
DO (1) DOP2005000050A (da)
ES (1) ES2334241T3 (da)
GT (1) GT200500063A (da)
IL (1) IL178168A0 (da)
MX (1) MXPA06011222A (da)
PA (1) PA8628601A1 (da)
PL (1) PL1734959T3 (da)
PT (1) PT1734959E (da)
SI (1) SI1734959T1 (da)
SV (1) SV2006002069A (da)
TW (1) TW200602040A (da)
WO (1) WO2005097122A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
EP2437744B1 (en) * 2009-06-03 2015-06-03 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
EP3941352A1 (en) 2019-03-19 2022-01-26 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
DE69621617T2 (de) * 1995-07-27 2003-01-02 Aventis Pharmaceuticals Inc., Bridgewater Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
GT200500063A (es) 2005-10-14
SI1734959T1 (sl) 2010-02-26
ATE446754T1 (de) 2009-11-15
PL1734959T3 (pl) 2010-03-31
US20070129403A1 (en) 2007-06-07
CY1109734T1 (el) 2014-09-10
CN1946399A (zh) 2007-04-11
DE602005017373D1 (de) 2009-12-10
EP1734959A2 (en) 2006-12-27
ES2334241T3 (es) 2010-03-08
IL178168A0 (en) 2006-12-31
CA2561162A1 (en) 2005-10-20
DOP2005000050A (es) 2005-11-30
WO2005097122A2 (en) 2005-10-20
EP2138176A1 (en) 2009-12-30
MXPA06011222A (es) 2007-01-16
PA8628601A1 (es) 2006-05-16
PT1734959E (pt) 2009-12-24
JP2007531730A (ja) 2007-11-08
AU2005231446A1 (en) 2005-10-20
WO2005097122A3 (en) 2006-02-02
EP1734959B1 (en) 2009-10-28
SV2006002069A (es) 2006-05-24
TW200602040A (en) 2006-01-16
CL2009001605A1 (es) 2009-11-27
KR20070010161A (ko) 2007-01-22
BRPI0509512A (pt) 2007-09-11
AR048197A1 (es) 2006-04-05

Similar Documents

Publication Publication Date Title
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DE602005027052D1 (de) Endoskopbehandlungssystem
DK1734959T3 (da) Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter
DK3121169T3 (da) Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2026819T3 (da) Forebyggelse og/eller behandling af Alzheimers sygdom
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
NO20070251A (no) Brønnbehandling
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
ZA200706113B (en) Method for the treatment of copper-bearing materials
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK1863899T3 (da) Hudbehandlingspræparater
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia